Home » Stocks » Vaccinex

Vaccinex, Inc. (VCNX)

Stock Price: $3.33 USD -0.14 (-4.03%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 55.43M
Revenue (ttm) 429,000
Net Income (ttm) -29.95M
Shares Out 16.36M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $3.33
Previous Close $3.47
Change ($) -0.14
Change (%) -4.03%
Day's Open 3.42
Day's Range 3.27 - 3.50
Day's Volume 46,759
52-Week Range 3.22 - 12.23

More Stats

Market Cap 55.43M
Enterprise Value 52.94M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.36M
Float 3.74M
EPS (basic) -2.16
EPS (diluted) -2.14
FCF / Share -1.88
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 197,854
Short Ratio 4.58
Short % of Float 2.99%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 129.20
PB Ratio n/a
Revenue 429,000
Operating Income -30.03M
Net Income -29.95M
Free Cash Flow -30.08M
Net Cash 2.49M
Net Cash / Share 0.15
Gross Margin 75.52%
Operating Margin -7,000.93%
Profit Margin -6,980.20%
FCF Margin -7,011.89%
ROA -206.56%
ROE -1,303.09%
ROIC 554.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(540.54% upside)
Current: 3.33
Target: 21.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-27.76%704.44%-71.52%-
Gross Profit0.32-0.31-0.070.20
Operating Income-32.02-27.28-21.10-20.26
Net Income-31.86-29.52-18.72-13.94
Shares Outstanding12.885.221.101.04
Earnings Per Share-2.47-5.65-19.90-25.27
Operating Cash Flow-30.72-25.28-21.39-19.72
Capital Expenditures-0.08-0.24-0.07-0.79
Free Cash Flow-30.79-25.51-21.46-20.51
Cash & Equivalents2.7819.724.181.66
Total Debt--2.811.04
Net Cash / Debt2.7819.721.370.62
Book Value-26.24-8.62-125-107
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaccinex, Inc.
Country United States
Employees 45
CEO Maurice Zauderer

Stock Information

Ticker Symbol VCNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VCNX


Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.